Skip to content

LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema

Lymfo-Veneuse Anastomosen Ter Preventie Van Lymphoedeem

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05601037
Acronym
LVARCT
Enrollment
80
Registered
2022-11-01
Start date
2021-06-30
Completion date
2026-12-27
Last updated
2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema, Breast Cancer

Brief summary

Lymphedema is defined as a chronic condition, caused by lymphostasis. A major part in the Western world consists of iatrogenic lymphedema caused by surgery to the lymph nodes of the axilla or groin. Prophylactic lymphovenous anastomosis (LVA) could be beneficial in the prevention of lymphedema of the extremities.

Detailed description

The investigator is performing a blinded randomized prospective study on 80 patients undergoing an axilla dissection for their breast cancer treatment. One group will receive a LVA at the time of their axilla dissection. Other group will receive standard of care. Follow-up is 2 year.

Interventions

PROCEDUREAxilla dissection + Lymphovenous anastomosis

surgical bypass between lymphatic vessel and vein

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

blinded randomized prospective

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* lymph node + breast cancer requiring dissection

Exclusion criteria

* previous lymphedema * BMI \>35

Design outcomes

Primary

MeasureTime frameDescription
The volume via circumferential measurements: swelling < 5%2 yearsComparing the volume of the arm at each study visit via circumferential measurements: swelling \< 5%

Countries

Belgium

Contacts

Primary ContactBernard Depypere, MD
bernard.depypere@ugent.be093325730
Backup ContactJessie De Kinder
jessie.dekinder@uzgent.be093321373

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026